In a conversation with Managed Healthcare Executive, Michael Abrams, M.A., managing partner at Numerof & Associates, painted ...

While the impact of Medicaid changes on employer-sponsored insurance remains to be seen, competition between providers is a ...

In an opinion article, investigators argue that gene therapies may not achieve their full potential if the innate inflammation in Duchenne muscular dystrophy is not effectively managed.

According to Regeneron, the drug is a bispecific antibody that binds to B-cell maturation antigen (BCMA) on cancerous plasma cells and CD3 on T cells, directing the immune system to attack and destroy ...

After a one-year follow-up, 10 of 12 patients given the islet cell therapy zimislecel no longer required insulin. Vertex ...

Climate change and air pollution are growing threats to public health, and new research suggests they may also worsen atopic ...

Physician ownership of facilities and joint ventures with major chains also increased substantially from 2005 to 2019.

To prepare for CMS’ new risk adjustment data validation (RADV) strategy, Medicare Advantage plans must take a coordinated, ...

FDA officials have determined that information regarding the risks for six CAR T-cell therapies can be communicated through product labeling, which includes a boxed warning for the risks of cytokine ...

Care gaps in women’s health are closing, thanks to increased cultural awareness of gendered healthcare disparities, according ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

Absent a federal committee’s recommendation, Duchenne muscular dystrophy advocates are trying to get states to adopt ...